Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer
Study now open for enrollment at leading academic medical centersCARY, N.C. and…
BC-led clinical trial points to safer care for critically ill patients
NEW WESTMINSTER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- A BC-led…
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreichs Ataxia on Monday, May 18, 2026
May 17, 2026 16:00 ET | Source: Design Therapeutics, Inc. CARLSBAD, Calif.,…
ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026
– Complete response (CR) observed in 70% (50/72) of evaluable patients with…
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
May 15, 2026 20:19 ET | Source: Regeneron Pharmaceuticals, Inc. The trial…
WhiteSwell Announces Primary Clinical Trial Results Simultaneously at Heart Failure 2026 Congress and in European Journal of Heart Failure related to the DELTA-HF Study in Acute Decompensated Heart Failure
GALWAY, Ireland, May 10, 2026 (GLOBE NEWSWIRE) -- WhiteSwell, a clinical-stage medtech…
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a…
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE:…
Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802,…
Celcuity’s Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
MINNEAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a…
